Effect of pharmacokinetic sampling methods on aminoglycoside dosing in critically ill surgery patients

Pharmacotherapy

Volumn 18, Issue 2 I, 1998, Pages 371-378

  Mann, Henry J ^a,e   Wittbrodt, Eric T ^b   Baghaie, Ali A ^c   Cerra, Frank B ^d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF THE SCIENCES   (United States)

^c TEXAS SOUTHERN UNIVERSITY   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e 5 130 WDH ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; GENTAMICIN; TOBRAMYCIN;

ADULT; AGED; ARTICLE; CRITICAL ILLNESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; FEMALE; GRAM NEGATIVE SEPSIS; HUMAN; MAJOR CLINICAL STUDY; MALE;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTI-BACTERIAL AGENTS; BLOOD SPECIMEN COLLECTION; CRITICAL ILLNESS; CROSS INFECTION; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENTAMICINS; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; REFERENCE VALUES; SAMPLE SIZE; SURGICAL WOUND INFECTION; TIME FACTORS; TOBRAMYCIN;

EID: 0031896017     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 1984;149:443-8.
2. Anonymous. Increase in national hospital discharge survey rates for septicemia - United States, 1979-87. MMWR 1990;39:31-4.
3. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74.
4. Dahlgren JG, Anderson ET, Hewitt WL. Gentamicin blood levels: a guide to nephrotoxicity. Antimicrob Agents Chemother 1975;8:58-62.
5. Moore RD, Smith CR, Lipsky JJ, et al. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 1984;100:352-7.
6. Jaresko GS, Boucher BA, Dole EJ, et al. Risk of renal dysfunction in critically ill trauma patients receiving aminoglycosides. Clin Pharm 1989;8:43-8.
7. DeBroe ME, Verbist L, Verpooten GA. Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man. J Antimicrob Chemother 1991;27(suppl C):41-7.
8. Humes HD, Weinberg JM, Knauss TC. Clinical and pathophysiologic aspects of aminoglycoside nephrotoxicity. Am J Kidney Dis 1982;3:5-29.
9. DeBroe ME, Paulus GJ, Verpooten GA, et al. Early effects of gentamicin, tobramycin, and amikacin on the human kidney. Kidney Int 1984;25:643-52.
10. Sawchuk RJ, Zaske DE, Cipolle RJ, et al. Kinetic model for gentamicin dosing with the use of individual patient parameters. Clin Pharmacol Ther 1977;21:362-9.
11. Schwartz SN, Pazin GJ, Lyon JA, et al. A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects. J Infect Dis 1978;138:499-505.
12. Blouin RA, Mann HJ, Griffen WO, et al. Tobramycin pharmacokinetics in morbidly obese patients. Clin Pharmacol Ther 1979;26:508-12.
13. Bauer LA, Blouin RA, Griffen WO, et al. Amikacin pharmacokinetics in morbidly obese patients. Am J Hosp Pharm 1980;37:519-22.
14. Sketris I, Lesar T, Zaske DE, et al. Effect of obesity on gentamicin pharmacokinetics. J Clin Pharmacol 1981;21:288-93.
15. Bauer LA, Edwards WAD, Dellinger EP, et al. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol 1983;24:643-7.
16. Zarowitz BJ, Pilla AM, Popovich J. Expanded gentamicin volume of distribution in patients with indicators of malnutrition. Clin Pharm 1990;9:40-4.
17. Hassan E, Ober JD. Predicted and measured aminoglycoside pharmacokinetic parameters in critically ill patients. Antimicrob Agents Chemother 1987;31:1855-8.
18. Mann HJ, Fuhs DW, Awang R, et al. Altered aminoglycoside pharmacokinetics in critically ill patients with sepsis. Clin Pharm 1987;6:148-53.
19. van Dalen R, Vree TB. Pharmacokinetics of antibiotics in critically ill patients. Intensive Care Med 1990;16:S235-8.
20. Hickling KG, Begg EJ, Perry RE, et al. Serum aminoglycoside clearance is predicted as poorly by renal aminoglycoside clearance as by creatinine clearance in critically ill patients. Crit Care Med 1991;19:1041-7.
21. Dasta JF, Armstrong DK. Variability in aminoglycoside pharmacokinetics in critically ill surgery patients. Crit Care Med 1988;16:327-30.
22. Fuhs DW, Mann HJ, Kubajak CAM, et al. Intrapatient variation of aminoglycoside pharmacokinetics in critically ill surgery patients. Clin Pharm 1988;7:207-13.
23. Zaske DE, Cipolle RJ, Rotschafer JC, et al. Individualizing amikacin regimens: accurate method to achieve therapeutic concentrations. Ther Drug Monit 1991;13:502-6.
24. Zaske DE, Cipolle RJ, Strate RJ. Gentamicin dosage requirements: wide interpatient variations in 242 surgery patients with normal renal function. Surgery 1980;87:164-9.
25. Kloth DD, Tegtmeier BR, Kong C, et al. Altered gentamicin pharmacokinetics during the perioperative period. Clin Pharm 1985;4:182-5.
26. Blouin RA, Brouwer KLR, Record KE, et al. Amikacin pharmacokinetics in morbidly obese patients undergoing gastric-bypass surgery. Clin Pharm 1985;4:70-2.
27. Operaoji EC, Cornwell EE, Hekmat E, et al. Aminoglycoside volume of distribution in postoperative patients with septic shock. Clin Pharm 1993;12:131-4.
28. Niemiec PW, Allo MD, Miller CF. Effect of altered volume of distribution on aminoglycoside levels in patients in surgical intensive care. Arch Surg 1987;122:207-12.
29. Perkins MW, Dasta JF, DeHaven B. Physiologic implications of mechanical ventilation on pharmacokinetics. Drug Intell Clin Pharm 1989;23:316-23.
30. Triginer C, Fernandez R, Izquierdo I, et al. Gentamicin pharmacokinetic changes related to mechanical ventilation [letter]. Drug Intell Clin Pharm 1989;23:923-4.
31. Martin C, Mallet M-N, Saux P, et al. Tobramycin dosing in mechanically ventilated patients. Inaccuracy of a "rule of thumb." J Antimicrob Chemother 1988;22:505-11.
32. Sampliner R, Perrier D, Powell R, et al. Influence of ascites on tobramycin pharmacokinetics. J Clin Pharmacol 1984;24:43-6.
33. Segal JL, Gray DR, Gordon SK, et al. Pharmacokinetics of gentamicin in patients with spinal cord injury. Clin Pharm 1984;3:418-20.
34. Townsend PL, Fink MP, Stein KL, et al. Aminoglycoside pharmacokinetics: dosage requirements and nephrotoxicity in trauma patients. Crit Care Med 1989;17:154-7.
35. Reed RL, Ericsson CD, Wu A, et al. The pharmacokinetics of prophylactic antibiotics in trauma. J Trauma 1992;32:21-7.
36. Tholl DA, Shikuma LR, Miller TQ, et al. Physiologic response of stress and aminoglycoside clearance in critically ill patients. Crit Care Med 1993;21:248-51.
37. Zaske DE, Strate RG, Kohls PR. Amikacin pharmacokinetics: wide interpatient variation in 98 patients. J Clin Pharmacol 1991;31:158-63.
38. Triginer C, Izquierdo I, Fernandez R, et al. Gentamicin volume of distribution in critically ill septic patients. Intensive Care Med 1990;16:303-6.
39. Summer WR, Michael JR, Lipsky JJ. Initial aminoglycoside levels in the critically ill. Crit Care Med 1983;11:948-50.
40. Chelluri L, Jastremski MS. Inadequacy of standard aminoglycoside loading doses in acutely ill patients. Crit Care Med 1987;15:1143-5.
41. Beckhouse, MJ, Whyte IM, Byth PL, et al. Altered aminoglycoside pharmacokinetics in the critically ill. Anaesth Intensive Care 1988;16:418-22.
42. Noone P, Parsons TMC, Pattison JR, et al. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J 1974;1:477-81.
43. Zaske DE, Bootman JL, Solem LB, et al. Increased burn patient survival with individualized dosages of gentamicin. Surgery 1982;91:142-9.
44. Whipple JK, Ausman RK, Franson T, et al. Effect of individualized pharmacokinetic dosing on patient outcome. Crit Care Med 1991;19:1480-5.
45. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
46. Drusano GL, Forrest A, Snyder MJ, et al. An evaluation of optimal sampling strategy and adaptive study design. Clin Pharmacol Ther 1988;44:232-8.
47. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981;9: 503-13.
48. Torres MJ, Kern JW, Gill MA, et al. Comparison of serum sampling methods for estimating gentamicin pharmacokinetic variables. Clin Pharm 1983;2:353-5.
49. Bottger H-C, Oellerich M, Sybrecht GW. Use of aminoglycosides in critically ill patients: individualization of dosage using Bayesian statistics and pharmacokinetic principles. Ther Drug Monit 1988;10:280-6.
50. Lavezo LA, Davis RL. Two- versus three-sample method for estimating gentamicin pharmacokinetic values. Am J Hosp Pharm 1994;51:1021-4.